Table of Content

Open Access iconOpen Access

ARTICLE

Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo

Antonello Di Paolo1, Paola Orlandi1, Teresa Di Desidero, Romano Danesi, Guido Bocci

Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
1 These authors provided equal contribution to this work.

Oncology Research 2017, 25(7), 1129-1140. https://doi.org/10.3727/096504017X14841698396900

Abstract

The combination of folinate salts to 5-fluoruracil (5-FU)-based schedules is an established clinical routine in the landscape of colorectal cancer treatment. The aim of this study was to investigate the pharmacological differences between the sequential administration of folinate salts (1 h before, as in clinical routine) followed by 5-FU and the simultaneous administration of both drugs. Proliferation and apoptotic assays were performed on human colon cancer cells exposed to 5-FU, calcium (CaLV), or disodium (NaLV) levofolinate or their simultaneous and sequential combination for 24 and 72 h. TYMS and SLC19A1 gene expression was performed with real-time PCR. In vivo experiments were performed in xenografted nude mice, which were treated with 5-FU escalating doses and CaLV or NaLV alone or in simultaneous and sequential combination. The simultaneous combination of folinate salts and 5-FU was synergistic (NaLV) or additive (CaLV) in a 24-h treatment in both cell lines. In contrast, the sequential combination of both folinate salts and 5-FU was antagonistic at 24 and 72 h. The simultaneous combination of 5-FU and NaLV or CaLV inhibited TYMS gene expression at 24 h, whereas the sequential combination reduced SLC19A1 gene expression. In vivo experiments confirmed the enhanced antitumor activity of the 5-FU + NaLV simultaneous combination with a good toxicity profile, whereas the sequential combination with CaLV failed to potentiate 5-FU activity. In conclusion, only the simultaneous, but not the consecutive, in vitro and in vivo combination of 5-FU and both folinate salt formulations potentiated the antiproliferative effects of the drugs.

Keywords


Cite This Article

APA Style
Paolo, A.D., Orlandi, P., Desidero, T.D., Danesi, R., Bocci, G. (2017). Simultaneous, but not consecutive, combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro and in vivo. Oncology Research, 25(7), 1129-1140. https://doi.org/10.3727/096504017X14841698396900
Vancouver Style
Paolo AD, Orlandi P, Desidero TD, Danesi R, Bocci G. Simultaneous, but not consecutive, combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro and in vivo. Oncol Res. 2017;25(7):1129-1140 https://doi.org/10.3727/096504017X14841698396900
IEEE Style
A.D. Paolo, P. Orlandi, T.D. Desidero, R. Danesi, and G. Bocci "Simultaneous, But Not Consecutive, Combination With Folinate Salts Potentiates 5-Fluorouracil Antitumor Activity In Vitro and In Vivo," Oncol. Res., vol. 25, no. 7, pp. 1129-1140. 2017. https://doi.org/10.3727/096504017X14841698396900



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 34

    View

  • 124

    Download

  • 0

    Like

Share Link